Dec 26 2025HEALTH
Pfizer's Hympavzi Faces Setback: What You Need to Know
Pfizer's stock took a hit recently, and it's all tied to a serious issue with one of their drugs. A patient in a long-term study for Hympavzi, a treatment for hemophilia, passed away due to severe complications. This news came out in December 2025, and it's got people talking. The patient had hemop
reading time less than a minute
